197 related articles for article (PubMed ID: 27462066)
41. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.
Fukumoto S
Calcif Tissue Int; 2016 Apr; 98(4):334-40. PubMed ID: 26126937
[TBL] [Abstract][Full Text] [Related]
42. Contribution of imaging to the diagnosis and follow up of X-linked hypophosphatemia.
Adamsbaum C; Laredo JD; Briot K; Linglart A
Arch Pediatr; 2021 Oct; 28(7):594-598. PubMed ID: 34583869
[TBL] [Abstract][Full Text] [Related]
43. FGF23-related hypophosphatemic rickets preceding the onset of systemic lupus erythematosus: A juvenile case.
Tabei Y; Ohtsu Y; Shimada M; Wada A; Hamajima E; Osawa Y; Takizawa T
Clin Case Rep; 2024 Jan; 12(1):e8420. PubMed ID: 38223518
[TBL] [Abstract][Full Text] [Related]
44. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
45. [Rickets].
Yasuda T
Clin Calcium; 2009 Jan; 19(1):109-16. PubMed ID: 19122271
[TBL] [Abstract][Full Text] [Related]
46. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
47. A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
Ichikawa S; Gerard-O'Riley RL; Acton D; McQueen AK; Strobel IE; Witcher PC; Feng JQ; Econs MJ
Endocrinology; 2017 Mar; 158(3):470-476. PubMed ID: 28005411
[TBL] [Abstract][Full Text] [Related]
48. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.
Bai X; Miao D; Li J; Goltzman D; Karaplis AC
Endocrinology; 2004 Nov; 145(11):5269-79. PubMed ID: 15284207
[TBL] [Abstract][Full Text] [Related]
49. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
50. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak.
Rendina D; Mossetti G; De Filippo G; Cioffi M; Strazzullo P
J Clin Endocrinol Metab; 2006 Mar; 91(3):959-63. PubMed ID: 16352682
[TBL] [Abstract][Full Text] [Related]
51. Fibroblast growth factor-23 and renin-angiotensin system levels in vitamin-D-dependent rickets type I.
Cuervo C; Abitbol CL; Zilleruelo GE; Freundlich M
Pediatr Nephrol; 2016 Jul; 31(7):1189-93. PubMed ID: 26939683
[TBL] [Abstract][Full Text] [Related]
52. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
53. Polyostotic osteolysis and hypophosphatemic rickets with elevated serum fibroblast growth factor 23: A case report.
Sato T; Muroya K; Asakura Y; Yachie A; Nishimura G; Aida N; Machida J; Tanaka Y; Hasegawa T; Adachi M
Am J Med Genet A; 2015 Oct; 167A(10):2430-4. PubMed ID: 26059403
[TBL] [Abstract][Full Text] [Related]
54. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene.
Saito T; Nishii Y; Yasuda T; Ito N; Suzuki H; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2009 Oct; 161(4):647-51. PubMed ID: 19581284
[TBL] [Abstract][Full Text] [Related]
55. [Regulation and disorders of calcium and phosphate metabolism].
Michigami T
Clin Calcium; 2014 Feb; 24(2):169-75. PubMed ID: 24473349
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
57. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets.
Imel EA; Liu Z; Coffman M; Acton D; Mehta R; Econs MJ
J Bone Miner Res; 2020 Feb; 35(2):231-238. PubMed ID: 31652009
[TBL] [Abstract][Full Text] [Related]
58. Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Saeedi R; Jiang SY; Holmes DT; Kendler DL
Calcif Tissue Int; 2014 Jun; 94(6):665-8. PubMed ID: 24706031
[TBL] [Abstract][Full Text] [Related]
59. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
60. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
Imel EA; Peacock M; Gray AK; Padgett LR; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2011 Nov; 96(11):3541-9. PubMed ID: 21880793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
